Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

42,576 stories, page 530 of 710

Advanced search

🌍Jul 14discoverynews.google.comTier 3 · Aggregated media

FDA Clears First At-Home Starter Dose for Alzheimer’s Drug Leqembi, Sending Biogen Shares Up 5%

finance.biggo.comOriginal source

🌍Jul 14discoverynews.google.comTier 3 · Aggregated media

FDA Set to Decide on a New Non-Stimulant ADHD Drug for Children and Adults on July 24

Medical DailyOriginal source

🌍Jul 14discoverynews.google.comTier 3 · Aggregated media

AbbVie pharmaceutical project moves forward in Durham: 'Huge deal'

ABC11 NewsOriginal source

🌍Jul 14discoverynews.google.comTier 3 · Aggregated media

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease

BiogenOriginal source

🌍Jul 14discoverynews.google.comTier 3 · Aggregated media

FDA clears at-home starting dose for Alzheimer's drug Leqembi

MSNOriginal source

🌍Jul 14discoverynews.google.comTier 3 · Aggregated media

Russian Billionaire Wins Fight to Boot Manager of Biotech Fund

Bloomberg.comOriginal source

🌍Jul 14discoverynews.google.comTier 3 · Aggregated media

Boulder biotech unloads muscular dystrophy drug for up to $2.65 billion

The Business JournalsOriginal source

🌍Jul 14discoverynews.google.comTier 3 · Aggregated media

Alopecia Drug Bempikibart Clears Phase 2a Bar, Works in Patients JAK Inhibitors Failed

Tech TimesOriginal source

🌍Jul 14discoverynews.google.comTier 3 · Aggregated media

Psychedelics: FDA offers clarifications, compromises in final clinical trial guidance

RAPSOriginal source

🌍Jul 14discoverynews.google.comTier 3 · Aggregated media

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

ETF DatabaseOriginal source

🌍Jul 14discoverynews.google.comTier 3 · Aggregated media

Novartis’ Carrie Bracco Says Flexibility in Biomanufacturing is the Most Underaddressed Need for Emerging Biotech Companies

BioPharm InternationalOriginal source

🌍Jul 14discoverynews.google.comTier 3 · Aggregated media

Senate Aging Panel Probes Foreign Drug Supply Control

Legis1Original source

🌍Jul 14discoverynews.google.comTier 3 · Aggregated media

Pro-Life AG Suggests a Reason Why the Trump Admin Hasn’t Cracked Down on the Abortion Pill

Daily SignalOriginal source

🌍Jul 14discoverynews.google.comTier 3 · Aggregated media

HHS & VA Announce Bold, Comprehensive Partnership to Advance Rapid-Acting Mental Health Treatments for Veterans

HHS.govOriginal source

🌍Jul 14discoverynews.google.comTier 3 · Aggregated media

‘Profits over safety’: James Uthmeier launches probe into cancer-linked food additive

Florida PoliticsOriginal source

🌍Jul 14discoverynews.google.comTier 3 · Aggregated media

FDA Issues CRL to Elevar Therapeutics | PharmExec

Pharmaceutical ExecutiveOriginal source

🌍Jul 14discoverynews.google.comTier 3 · Aggregated media

FDA accepts BioMarin application for full VOXZOGO approval

Investing.com UKOriginal source

🌍Jul 14discoverynews.google.comTier 3 · Aggregated media

Learning from the last decade of gene therapies

Drug Discovery NewsOriginal source

🌍Jul 14discoverynews.google.comTier 3 · Aggregated media

Own Regeneron For Biotech Growth? Incyte Is Making Its Case.

TrefisOriginal source

🌍Jul 14discoverynews.google.comTier 3 · Aggregated media

Malvern's Ocugen strikes up to $255M licensing deal

The Business JournalsOriginal source

🌍Jul 14discoverynews.google.comTier 3 · Aggregated media

Attention Q32 Bio investors: take profits before QTTB shares crash again

InvezzOriginal source

🌍Jul 14discoverynews.google.comTier 2 · Trade media

“Hub-and-spoke” drug manufacturing set to benefit from new FDA rule

Pharmaceutical TechnologyOriginal source

🌍Jul 14discoverynews.google.comTier 3 · Aggregated media

FDA Recalls and Warnings: Generic Adderall XR Mix-Up, Subpotent Levothyroxine, Moringa Supplements Tainted with Salmonella

MedShadow FoundationOriginal source

🌍Jul 14discoverynews.google.comTier 2 · Trade media

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer

BioSpaceOriginal source

🌍Jul 14discoverynews.google.comTier 3 · Aggregated media

Ocugen Signs $255M MENA Licensing Deal for OCU400 Gene Therapy to Treat Retinitis Pigmentosa

MinichartOriginal source

🌍Jul 14discoverynews.google.comTier 3 · Aggregated media

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions

The Globe and MailOriginal source

🌍Jul 14discoverynews.google.comTier 3 · Aggregated media

Retatrutide Posts Strong Phase 3 Results in Type 2 Diabetes, but Is It Truly the Next Generation Beyond GLP-1?

trialsitenews.comOriginal source

🇯🇵Jul 14CROen.cmicgroup.comTier 2 · Direct publisher

BIO Asia-Taiwan 2026

CMIC Group JapanOriginal source

🌍Jul 14discoverynews.google.comTier 3 · Aggregated media

BofA raises Krystal Biotech stock price target on Vyjuvek growth

Investing.comOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

CriteriaCaixa targets €300M for biotech and tech by 2030

European Biotechnology MagazineOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Pune: FDA Seizes Suspected Adulterated Food Stock Worth ₹37.61 Lakh Across Seven Locations

PUNE PULSEOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Industry analysis says innovative medicines deliver six-fold return in Greece

The Pharma LetterOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Ocugen signs OCU400 MENA license agreement

grafa.comOriginal source

🌍Jul 13discoverynews.google.comTier 2 · Trade media

FDA's latest onshoring move homes in on streamlined facility registration, foreign plant scrutiny

Fierce PharmaOriginal source

🇺🇰Jul 13Researchphar.cam.ac.ukTier 2 · Direct publisher

Celebrating our students at our Final Year Talks 2026

Cambridge Pharma ResearchOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

FDA takes first step toward ‘de facto’ ad ban: What to know

PRWeekOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Here's How Much $100 Invested In State Street SPDR S&P Biotech ETF 20 Years Ago Would Be Worth Today

BenzingaOriginal source

🇯🇵Jul 13Researchriken.jpTier 2 · Direct publisher

Mikiko Sodeoka elected as International Honorary Member of the American Academy of Arts & Sciences

RIKENOriginal source

🌍Jul 13Mediasaama.comTier 2 · Direct publisher

FDA Advances Real-Time Clinical Trials: What It Means for AI-Driven Drug Development

SaamaOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

AI-enabled drug discovery collaboration with VERAXA biotech to support growing BiTAC® pipeline

EIN PresswireOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

€300 million for Iberian BioTech and DeepTech as CriteriaCaixa rebrands its VC arm

EU-StartupsOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

FDA Accepts NDA for Mezigdomide Combo in R/R Multiple Myeloma

CancerNetworkOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Ocugen, Inc.Original source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer’s Drug Study Details

Barron'sOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Agenus (AGEN) Stock Jumps 13% on Major $340M Financing Agreement

BlockonomiOriginal source

🇪🇺Jul 13Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: Targeted Genetic Manipulation of Muscle Stem Cells in vivo Towards New Treatment Strategies Against Muscular Dystrophies

CORDISOriginal source

🇪🇺Jul 13Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: CellTuned: AI-driven regulatory genomics for precision therapy

CORDISOriginal source

🇪🇺Jul 13Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: STRIALIS: A platform to mechanistically subtype and treat Parkinson's disease.

CORDISOriginal source

🇪🇺Jul 13Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: A doctoral training programme for next-generation LUNG-targeted non-viral GENEtic MEDicines

CORDISOriginal source

🇪🇺Jul 13Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: CDT-net: The Cardiovascular Digital Twin Network

CORDISOriginal source

🇪🇺Jul 13Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: Discovery of druggable antiviral targets across viral families through chemical probing

CORDISOriginal source

🇺🇸Jul 13CROmedidata.comTier 2 · Direct publisher

Virtual Twins: What They Are & Their Impact in Life Sciences

Medidata SolutionsOriginal source

🌍Jul 13discoverynews.google.comTier 2 · Trade media

Tris Pharma’s CRL for narcolepsy drug; Agenus abandons Phase 3 CRC trial

Endpoints NewsOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Pharmaceutical Companies Evaluate Financial and Operational Impact of Transitioning to Reusable Plastic Pallets

geneonline.comOriginal source

🌍Jul 13discoverynews.google.comTier 2 · Trade media

9 of the Top 10 Pharma Manufacturers Partner with Redi Health to Lead the Next-Generation Patient Experience

Fierce PharmaOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Practical AI applications for biotech R&D

News-MedicalOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Oncolytics Biotech Shares Climb Ahead of Planned FDA Meeting on REO 033 Trial (ONCY)

Yahoo FinanceOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

FDA Issues CRL to Elevar Therpaeutics for Combination of Rivoceranib and Camrelizumab

Pharmaceutical ExecutiveOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Alzheimer’s Drug Targets Astrocytes, Not Amyloid: Pepinemab Advances to Phase 2b

Tech TimesOriginal source

🌍Jul 13discoverynews.google.comTier 3 · Aggregated media

Alopecia Areata Drug Holds Hair Regrowth After Patients Stop Taking It

Tech TimesOriginal source